Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal ...

CAR T-cell therapies have demonstrated efficacy in treating blood cancers but, so far, their safety and effectiveness in ...

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for ...

A survey of the nation's oncologists showed that professional burnout has reached a new high (59% vs 45% in 2013), and fewer ...

Brain metastases are one of the most severe complications of melanoma, the most aggressive type of skin cancer. Researchers ...

The firm will make its artificial intelligence-based Lunit SCOPE IO platform available to SITC member researchers.

San Diego, USA-based Turnstone Biologics yesterday announced that it has completed an assessment of its business and ...

Researchers reveal that gut microbiota influence the effectiveness of immune checkpoint inhibitors (ICIs) in cancer treatment ...

A spokesperson for the Cholangiocarcinoma Foundation writes that experimental cancer trials saved her life and could save the ...

Turnstone, which went public via an $80 million IPO in 2023, ended September 2024 with $45.3 million to hand, which the ...